Gilead to Acquire Arcellx at $115 + CVRs

Gilead announced on 2026-02-23 that it will acquire Arcellx for $115 per share plus contingent value rights (CVRs). The deal was presented as a strategic acquisition to expand Gilead's oncology portfolio and specifically its CAR‑T capabilities. The disclosed asset of note is Arcellx's CAR‑T candidate, anitocabtagene autoleucel, for which a BLA has been filed for multiple myeloma.

The acquisition is consistent with Gilead's stated strategy to expand oncology through CAR‑T therapies alongside existing products such as Yescarta and Tecartus. Gilead's broader R&D priorities also include virology programs (lenacapavir for HIV PrEP) and antibody‑drug conjugates (Trodelvy) and HDV treatment candidates (bulevirtide). Adding an Arcellx CAR‑T program augments the company's oncology pipeline and supports the stated multi‑year push into cell therapy. From a commercial standpoint, Gilead sells the majority of product volumes through U.S. wholesalers (90%+ of sales) and distributes internationally via third‑party partners; the company generated total product sales of $6,613 million in Q1 2025, with the U.S. representing roughly 70% of product sales. Integrating an additional CAR‑T franchise would sit alongside Gilead's existing oncology revenue stream (oncology ≈ $757M in Q1 2025).

Key risk factors that remain relevant to investors include regulatory and clinical risk tied to BLA filings and ongoing trials; Gilead's public filings emphasize the potential for clinical delays or failures and related impairments. The company has recorded material IPR&D and intangible asset balances and impairments in recent periods (for example, IPR&D balances and a prior impairment tied to Trodelvy NSCLC work). Gilead's sustainable advantages are tied to finite‑lived patents and switching costs from established HIV single‑tablet regimens, but the company faces patent erosion risk and competitive pressure. Legal risks, including product liability litigation, are also noted in Gilead's risk disclosures. Investors should view the Arcellx purchase in the context of these existing program and regulatory risks rather than as a guaranteed near‑term earnings driver.